Loading company
Change Agents Corporation.
CHGA · Nasdaq · ·
$1.960.0%Sep 29 close
- 1M
- -31.3%
- 6M
- -82.8%
- 1Y
- -95.9%
- 5Y
- -99.9%
CHGA · Nasdaq · ·
$1.960.0%Sep 29 close
The quarter ending September 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2025 | 3 months toSep 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $350.1K | $345.2K | +1.43% |
| Profit | -$2.2M | -$13.5M | +83.81% |
| Profit per share | -$0.14 | -$6.22 | +97.75% |
| Free Cash Flow | -$796.3K | -$2M | +59.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Change Agents Corporation. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Change Agents Corporation.’s Item 2.02 8-K filed April 27, 2023; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.